182 related articles for article (PubMed ID: 35354905)
21. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
22. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
[TBL] [Abstract][Full Text] [Related]
23. EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.
Gollavilli PN; Pawar A; Wilder-Romans K; Natesan R; Engelke CG; Dommeti VL; Krishnamurthy PM; Nallasivam A; Apel IJ; Xu T; Qin ZS; Feng FY; Asangani IA
Cancer Res; 2018 Aug; 78(16):4760-4773. PubMed ID: 29898995
[TBL] [Abstract][Full Text] [Related]
24. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
25. Loss of Stag2 cooperates with EWS-FLI1 to transform murine Mesenchymal stem cells.
El Beaino M; Liu J; Wasylishen AR; Pourebrahim R; Migut A; Bessellieu BJ; Huang K; Lin PP
BMC Cancer; 2020 Jan; 20(1):3. PubMed ID: 31898537
[TBL] [Abstract][Full Text] [Related]
26. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
27. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
28. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.
Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD
Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901
[TBL] [Abstract][Full Text] [Related]
29. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
[TBL] [Abstract][Full Text] [Related]
30. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
[TBL] [Abstract][Full Text] [Related]
31. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
[TBL] [Abstract][Full Text] [Related]
32. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
33. EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Iniguez AB; Stolte B; Wang EJ; Conway AS; Alexe G; Dharia NV; Kwiatkowski N; Zhang T; Abraham BJ; Mora J; Kalev P; Leggett A; Chowdhury D; Benes CH; Young RA; Gray NS; Stegmaier K
Cancer Cell; 2018 Feb; 33(2):202-216.e6. PubMed ID: 29358035
[TBL] [Abstract][Full Text] [Related]
34. Regulation of FAS exon definition and apoptosis by the Ewing sarcoma protein.
Paronetto MP; Bernardis I; Volpe E; Bechara E; Sebestyén E; Eyras E; Valcárcel J
Cell Rep; 2014 May; 7(4):1211-26. PubMed ID: 24813895
[TBL] [Abstract][Full Text] [Related]
35. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.
Yuan B; Ji W; Xia H; Li J
Mol Med Rep; 2018 Mar; 17(3):4291-4298. PubMed ID: 29328472
[TBL] [Abstract][Full Text] [Related]
36. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.
De Vito C; Riggi N; Suvà ML; Janiszewska M; Horlbeck J; Baumer K; Provero P; Stamenkovic I
PLoS One; 2011; 6(8):e23592. PubMed ID: 21853155
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of HOX genes is prevalent in Ewing sarcoma and is associated with altered epigenetic regulation of developmental transcription programs.
Svoboda LK; Harris A; Bailey NJ; Schwentner R; Tomazou E; von Levetzow C; Magnuson B; Ljungman M; Kovar H; Lawlor ER
Epigenetics; 2014 Dec; 9(12):1613-25. PubMed ID: 25625846
[TBL] [Abstract][Full Text] [Related]
38. Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.
Stoll G; Surdez D; Tirode F; Laud K; Barillot E; Zinovyev A; Delattre O
Nucleic Acids Res; 2013 Oct; 41(19):8853-71. PubMed ID: 23935076
[TBL] [Abstract][Full Text] [Related]
39. Trabectedin Inhibits EWS-FLI1 and Evicts SWI/SNF from Chromatin in a Schedule-dependent Manner.
Harlow ML; Chasse MH; Boguslawski EA; Sorensen KM; Gedminas JM; Kitchen-Goosen SM; Rothbart SB; Taslim C; Lessnick SL; Peck AS; Madaj ZB; Bowman MJ; Grohar PJ
Clin Cancer Res; 2019 Jun; 25(11):3417-3429. PubMed ID: 30723142
[TBL] [Abstract][Full Text] [Related]
40. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]